Cogent Biosciences, Inc.
NASDAQ:COGTBiotechnology
Healthcare
$27.74 +2.60%
+$0.88 today
- Market cap
- $4.83B
- Beta
- 0.35
- P/E (TTM)
- -6.6
- EPS (TTM)
- -$5.26
52W Low $6.92High $43.73
Volume 1.68M
Average 2.15M
Balance Sheet
Inspect the capital base behind the business.
Assets
$937.61M
FY 2025 · Annual
+185.9% YoYLiabilities
$301.24M
FY 2025 · Annual
+320.7% YoYEquity
$636.37M
FY 2025 · Annual
+148.3% YoYBalance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 219.68M | 139.89M | 53.23M | 98.17M | 312.01M |
| Short-term Investments | 0 | 119.39M | 212.48M | 188.91M | 588.75M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 1.26M | 5.06M | 9.4M | 9.59M |
| Total Current Assets | 222.63M | 264.97M | 270.77M | 296.47M | 910.36M |
| Property, Plant & Equipment (Net) | 4.48M | 31.1M | 30.34M | 26.56M | 23.54M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 1.26M | 0 | 7.46M | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.73M | 4.75M | 4.86M | 4.86M | 3.72M |
| Total Non-current Assets | 9.46M | 35.84M | 42.67M | 31.43M | 27.25M |
| Total Assets | 232.09M | 300.81M | 313.44M | 327.9M | 937.61M |
| Account Payables | 3.48M | 5.84M | 10.66M | 12.01M | 9.5M |
| Short-term Debt | 0 | 0 | 0 | 0 | 1.55M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 3.06M | 1.7M | 0 | 0 | 0 |
| Other Current Liabilities | 3.62M | 6.47M | 10.32M | 12.63M | 52.9M |
| Total Current Liabilities | 17.08M | 26.85M | 38.17M | 55.71M | 63.95M |
| Long-term Debt | 0 | 0 | 0 | 0 | 237.25M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | (14.32M) |
| Total Non-current Liabilities | 831K | 18.23M | 17.47M | 15.9M | 237.28M |
| Total Liabilities | 17.91M | 45.08M | 55.64M | 71.61M | 301.24M |
| Common Stock | 44K | 70K | 86K | 110K | 161K |
| Retained Earnings | (270.97M) | (411.21M) | (603.62M) | (859.48M) | (1.19B) |
| Accumulated OCI | (0) | (104K) | 246K | 447K | 355K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 214.18M | 255.74M | 257.8M | 256.29M | 636.37M |
| Total Debt | 3.16M | 19.65M | 18.85M | 17.47M | 253.15M |
| Net Debt | (216.53M) | (120.24M) | (34.38M) | (80.7M) | (58.86M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $181.2M |
| Short-term Investments | $611.1M |
| Other Current | $12.5M |
| Total Current Assets | $804.8M |
| PP&E (Net) | $27.4M |
| Other Non-current | $2.4M |
| Total Non-current Assets | $29.7M |
| Total Assets | $834.5M |
Analysis
Selected assets total $834.5M for Latest. The largest visible component is Short-term Investments at $611.1M, about 73.2% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 5, 2026 | |
| 8-K | Current report | Sep 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 31, 2026 |
How much cash does COGT have?
Cogent Biosciences, Inc. (COGT) reported $312.01M in cash and equivalents in fiscal 2025.
How much debt does COGT carry?
Cogent Biosciences, Inc. (COGT) reported $253.15M of total debt, with net debt of -$58.86M.
Continue the stock analysis
Jump to another research area for this company.